2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: modification of target structure to minimize reactive metabolite formation.

Weinberg, Linda R; Albom, Mark S; Angeles, Thelma S; Breslin, Henry J; Gingrich, Diane E; Huang, Zeqi; Lisko, Joseph G; Mason, Jennifer L; Milkiewicz, Karen L; Thieu, Tho V; Underiner, Ted L; Wells, Gregory J; Wells-Knecht, Kevin J; Dorsey, Bruce D.
Bioorg Med Chem Lett; 21(24): 7325-30, 2011 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-22041060